No Data
No Data
No Data
No Data
No Data
Global Market for Exosome Diagnostics, Therapeutics, and Research Tools (2021-2028) Featuring Bio-Techne, Exosomics, and System Biosciences - An Evaluation of New Commercial Opportunities and Emerging Trends
Yahoo FinanceApr 24 04:20 ET
Getting In Cheap On Bio-Techne Corporation (NASDAQ:TECH) Is Unlikely
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may consider Bio-Techne Corporation (NASDAQ:TECH) as a stock to avoid entirely with its
Simply Wall StApr 19 07:08 ET
Navigating 4 Analyst Ratings For Bio-Techne
In the preceding three months, 4 analysts have released ratings for Bio-Techne (NASDAQ:TECH), presenting a wide array of perspectives from bullish to bearish.Summarizing their recent assessments, the
BenzingaApr 18 12:01 ET
Bio-Techne Price Target Cut to $82.00/Share From $85.00 by Deutsche Bank
Bio-Techne Price Target Cut to $82.00/Share From $85.00 by Deutsche Bank
Dow JonesApr 18 08:21 ET
Bio-Techne Is Maintained at Buy by Deutsche Bank
Bio-Techne Is Maintained at Buy by Deutsche Bank
Dow JonesApr 18 08:21 ET
Bio-Techne Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/18/2024 28.97% Deutsche Bank $85 → $82 Maintains Buy 02/02/2024 2.23% Stifel → $65 Downgrades Buy → Hol
BenzingaApr 18 08:11 ET
No Data
No Data